Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy by Zhang W et al.
Newcastle University e-prints  
Date deposited:  18th November 2011. 
Version of file:  Published 
Peer Review Status: Peer reviewed  
Citation for item: 
Zhang W, Becciolini A, Biggeri A, Pacini P, Muirhead CR. Second malignancies in breast cancer 
patients following radiotherapy: a study in Florence, Italy. Breast Cancer Research 2011, 13(2), R38. 
Further information on publisher website: 
http://breast-cancer-research.com 
Publisher’s copyright statement: 
© 2011 Zhang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the 
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly cited.  
http://dx.doi.org/10.1186/bcr2860 
Always use the definitive version when citing.   
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in Newcastle E-prints 
• The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU.  Tel. 0191 222 6000 
RESEARCH ARTICLE Open Access
Second malignancies in breast cancer patients
following radiotherapy: a study in Florence, Italy
Wei Zhang1*, Aldo Becciolini2, Annibale Biggeri3,4, Paolo Pacini and Colin R Muirhead1
Abstract
Introduction: Patients diagnosed with breast cancer are often treated with surgery followed by radiation therapy.
In this paper, we evaluate the effect that radiotherapy may have had on the subsequent risk of second
malignancies, including the possible influences of age at treatment and menopausal status.
Methods: In order to evaluate the long-term consequences of radiotherapy, a cohort study was conducted based
on clinical records for 5,248 women treated for breast cancer in Florence (Italy), with continuous follow-up from
1965 to 1994. The Cox proportional hazards model for ungrouped survival data was used to estimate the relative
risk for second cancer after radiotherapy.
Results: This study indicated an increased relative risk of all second cancers combined following radiotherapy (1.22,
95% CI: 0.88 to 1.69). The increased relative risk appeared five or more years after radiotherapy and appeared to be
highest amongst women treated after the menopause (1.61, 95% CI: 1.13 to 2.29). Increased relative risks were
observed specifically for leukaemia (8.13, 95% CI: 0.96 to 69.1) and other solid cancers (1.84, 95% CI: 1.06 to 3.16),
excluding contralateral breast cancer. For contralateral breast cancer, no raised relative risk was observed during
the period more than five years after radiotherapy.
Conclusions: The study indicated a raised risk of second malignancies associated with radiotherapy for breast
cancer, particularly for women treated after the menopause.
Introduction
Breast cancer is the most common type of cancer and
the major cause of cancer-related mortality among
women worldwide [1]. Many patients are diagnosed
with this disease each year and are often treated with
surgery followed by adjuvant radiation therapy [2]. The
use of radiation therapy has increased dramatically since
randomised trials in the 1980s showed equivalent out-
comes for patients treated with breast conserving sur-
gery and radiation therapy and those treated with
modified radical mastectomy [3-5]. With advances in
early diagnosis and treatment, breast cancer is becoming
an increasingly survivable disease resulting in a large
population of long-term survivors. Recent trials have
shown an overall survival benefit in favour of adjuvant
radiotherapy for breast cancer [6-8]. Nevertheless, there
is clear evidence for the association between radiation
exposure and cancer, especially from epidemiological
studies of survivors of the atomic bombings in Japan
[9,10], as well as from various studies of medically-
exposed groups [11]. In particular, irradiation of sur-
rounding tissues during breast radiotherapy can cause
second cancers to develop within these tissues [12,13].
The second malignancy refers to a new primary cancer
in a person who has survived an earlier cancer. The
probability of a radiation induced second malignancy
after radiotherapy is a topic that has been widely dis-
cussed [14-20]. While the benefit of radiotherapy should
outweigh the risks of developing subsequent cancers, it
is important to evaluate the long-term consequences of
breast cancer treatment.
The aim of this cohort study was to evaluate the inci-
dence of second primary cancers in a group of patients
treated with ionising radiation therapy for breast cancer
in comparison to patients not treated with ionising
radiation therapy. The study involved the analysis of
clinical records for female breast cancer patients treated
at the University of Florence (Italy) with radiotherapy
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and/or chemotherapy and/or hormonal therapy from
1965 to 1994 and who were subsequently followed-up
[21]. In this paper, we evaluate the effect that radiother-
apy may have had on the subsequent risk of second
malignancies, including the possible influence of age at
treatment and menopausal status.
Materials and methods
Data were collected on 5,248 patients with breast cancer
who were submitted to radiotherapy, chemotherapy,
hormonal therapy or no additional therapy at the Uni-
versity of Florence from June 1965 to December 1994.
All of the patients had received surgery for breast can-
cer. A treatment schedule of 2 Gy/day, 5 days/week, for
a total dose up to 60 Gy was used. Of these patients,
51.0% received radiotherapy and, for 74.0% of the
patients in this group, the exposed volume was the
breast only, compared with breast and lymphatic drai-
nage in 26.0% (in 17.5% the mammary chain and supra-
clavicular nodes were irradiated and in 8.5% the chest
wall was irradiated). The radiation source was a tele-
cobalt unit (dose rate 0.80 to 1.20 Gy/minute) or linear
accelerator. Different irradiation techniques with a 6
MV X-rays linear accelerator were used in later years,
namely: (a) two tangential fields; or (b) two tangential
fields plus direct irradiation with an electron beam of 12
MeV. Values calculated on 80 treated patients showed
that, in case (a), 12% of the total dose was absorbed at a
distance of 3 cm from the irradiated volume and that
this value decreased progressively to 2.4% at 12 cm. In
case (b), the absorbed dose was 3.8% of the total at 3
cm and 1.4% at 12 cm.
Follow-up for second malignancies was mainly con-
ducted through direct contact with the patients at regular
visits at out-patient clinics. On some visits information
on health status was also verified by accompanying rela-
tives. For this study, the cohort was assembled in 1996
and data were collected retrospectively.
Information on second malignancies was collected
from hospital records and pathology reports. Vital status
was assessed through demographic files at the munici-
pality of residence of each patient. Death certificates
were obtained from Mortality Registers at municipality
of death for those deceased before 1981, and at the
Local Health Unit thereafter. In 1984 the Tuscan Cancer
Register was established; therefore, all patients’ follow-
up data were cross-checked with the Tuscan Cancer
Registry from 1984 onwards. The end of follow-up for
the subjects was chosen to be the earliest of: date of sec-
ond cancer incidence, date of lost to follow-up, date of
death and 31 December 1994. Only six women were
lost to follow-up. The follow-up time among surviving
patients ranged from a minimum of 1 year to a maxi-
mum of 30 years, with a mean of 8 years. Table 1 lists
the number of patients by various therapy types and the
corresponding mean age-at-treatment. The overall aver-
age age at treatment was 54.7 years. However, women
who received radiotherapy only tended to be younger at
the time of treatment than those who received hormo-
nal therapy only, but older than those who received che-
motherapy only.
The Cox proportional hazards model for ungrouped
survival data [22] was used to estimate the relative risk
for second cancers after radiotherapy treatment and to
evaluate how the risk varied according to other factors.
In particular, the hazard function at a given time was
modelled as l(t) = l0(t)•exp[bx], where l0(t) is the base-
line hazard function, x represents one or more explana-
tory variables, and bx is the logarithm of the relative
risk. Parameter estimation and significance tests were
carried out using the Epicure software [23]. In particu-
lar, Wald-type confidence intervals were computed for
parameter estimates, whilst significance tests were based
on c2 approximations to the distribution of the log like-
lihood ratio. Some patients received chemotherapy and/
or hormonal therapy in both radiotherapy and non-
radiotherapy groups; therefore, the relative risks of sec-
ond cancers due to radiotherapy were reported both
unadjusted and adjusted for chemotherapy and hormo-
nal therapy to check if there were any confounding
effects from these therapies.
The researchers carrying out the study had no identifi-
able details of patients forwarded to them and, therefore,
ethical approval was not required under Italian laws
when the project was initiated in 1996.
Results
As shown in Table 2, among the 5,248 patients in the
cohort, 261 patients (5%) developed contralateral breast
cancer, 8 patients (0.15%) had leukaemia and a total of
118 patients (2.25%) developed other types of second
Table 1 Number of women who received various types of
therapy besides surgery
Type of therapy Number of
women (%)
Mean age-at-treatment
(years)
No therapy 1,457 (27.8) 57.4
Radiotherapy only 1,779 (33.9) 52.7
Hormonal therapy only 663 (12.6) 62.3
Chemotherapy only 443 (8.4) 46.3
Radio- and hormonal
therapy
553 (10.5) 57.8
Radio- and
chemotherapy
293 (5.6) 44.3
Hormonal and
chemotherapy
35 (0.7) 46.9
All three therapies 25 (0.5) 43.8
Total 5,248 (100) 54.7
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cancers at the end of follow-up. The specifics of other
types of second cancers are also shown in the table. The
median time to development of second malignancy is
3 years for contralateral breast cancer, 4.5 years for leu-
kaemia and 4.4 years for other cancers combined. Table
3 shows the estimated relative risks of all second cancers
combined among patients given radiotherapy, when
compared with other patients, according to the period
of follow-up. Relative risks both unadjusted and adjusted
for chemotherapy and hormonal therapy are presented.
Also shown in this table are the numbers of cases of
second cancers and the numbers of patients in the
radiotherapy and non-radiotherapy groups. Second can-
cers that appeared within the first two years after treat-
ment were considered to be synchronous and, hence
were excluded from the analysis. Table 3 shows relative
risks associated with radiotherapy for the follow-up peri-
ods of 2 to 4, 5 to 9, 10 to 14 and 15+ years respec-
tively. The relative risk was statistically significantly less
than one during the period two to four years after treat-
ment, either with or without adjustment for chemother-
apy and hormonal therapy, but was generally greater
than one at longer follow-up periods. Table 4 shows
that the unadjusted relative risk during the period five
or more years after treatment was 1.22 (95% CI 0.88,
1.69) and was similar when adjusted for other types of
therapy.
In light of this pattern, we examined risks of all sec-
ond cancers combined based on a follow-up of five or
more years. The relative risks are calculated according
to different age at the time of treatment groups (so
called age-at-treatment) as shown in Table 4. Raised
relative risks were observed in the 50 to 64 and 65+
year age-at-treatment groups, although none of the rela-
tive risks was statistically significantly different from
one. For a cohort under follow-up, ages of patients
increase as time of follow-up increases. The risk of
developing a second cancer at a particular age (so-called
age-at-risk) can also be calculated using the Cox propor-
tional hazards model. Therefore we examined the rela-
tive risk by age-at-risk to examine at what age the
second cancers were likely to occur, again based on a
follow-up of five or more years. As shown in Table 5,
Table 2 Sites of second malignancies
Second cancer
type
Numbers of total
second cancer
patients
Numbers of second
cancer patients with
radiotherapy
Contralateral
breast cancer
261 103
Leukaemia 8 7
Other type of
cancers combined
118 54
Lung 4 4
Liver 1 1
Kidney 6 3
Adrenal gland 1 0
Thymus 2 2
Non-Hodgkin
lymphoma
4 4
Bladder 1 1
Carcinoid 1 1
Thyroid 1 0
Larynx 2 0
Sarcoma 1 0
Tongue 1 0
Myeloma 1 0
Gastrointestinal
Colorectal 29 14
Esophagus 1 1
Gastric 18 8
Biliary
tract
1 1
Anus 3 0
Gynecologic
Cervix
corpus
17 7
Cervix
uteri
6 2
Uterus 1 1
Ovary 7 3
Skin
Melanoma 6 0
Non-
melanoma
1 1
Basel cell
carcinoma
2 0
Table 3 Relative risk of all second cancers among patients given radiotherapy, by period of follow-up
Follow-up
period (years)
RRa unadjusted for chemotherapy and
hormonal therapy (95% CIb)
RRa adjusted for chemotherapy and
hormonal therapy (95% CIb)
Case/women with
radiotherapy
Cases/women with
no radiotherapy
2 to 4 0.52 (0.33, 0.82)* 0.44 (0.28, 0.70)* 37/2,339 (1.6%) 53/2,377 (2.2%)
5 to 9 1.20 (0.79, 1.82) 1.08 (0.71, 1.65) 43/1,267 (3.4%) 56/1,813 (3.1%)
10 to 14 1.40 (0.75, 2.64) 1.34 (0.71, 2.52) 16/390 (4.1%) 28/972 (2.9%)
15+ 0.99 (0.41, 2.41) 1.13 (0.46, 2.77) 14/230 (6.0%) 10/307 (3.3%)
*P <0.05.
aRelative risk.
bConfidence interval.
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raised risks were observed in the 50 to 64 and 65+ year
age-at-risk groups and the relative risk in the latter
group was statistically significantly greater than one
(unadjusted RR 1.69, 95% CI 1.05, 2.73).
Since the 50 to 64 and 65+ year age-at-treatment
groups largely or entirely consist of post-menopausal
patients, we examined the relative risk of all second can-
cers combined in relation to menopausal status at the
time of treatment. Table 6 shows the relative risk for
radiotherapy separately for pre-menopausal and post-
menopausal patients. Since some patients had gone
through ovariectomy, they were analysed as a separate
group. Table 6 indicates that patients who had under-
gone ovariectomy or who were post-menopausal at the
time of treatment had a higher risk than did pre-meno-
pausal patients, although only for the post-menopausal
groups was the relative risk statistically significantly
greater than one. A heterogeneity test showed that the
relative risk differed significantly between these three
groups (P = 0.003).
Table 7 examines the relative risk for some specific
types of second cancer. Leukaemia, contralateral breast
cancer which refers to cancer in the opposite breast in a
person with a history of breast cancer, and all other can-
cers combined are considered here. For leukaemia, the
follow-up period was chosen to be two years or more
following treatment, in view of the evidence from other
studies showing a short latency period for radiation-
induced leukaemia [11], whilst the follow-up period was
chosen to be five years or more for other types of can-
cers. After adjustment for chemotherapy and hormonal
therapy, the relative risk was 6.67 (95% CI 0.76, 58.00)
for leukaemia and 1.70 (95% CI 0.98, 2.94) for all second
cancers other than leukaemia and contralateral breast
cancer combined, based on 7 and 29 cases respectively
among irradiated patients. In contrast, there was no
raised relative risk of contralateral breast cancer; after
adjustment for chemotherapy and hormonal therapy,
the relative risk was 0.82 (95% CI 0.54, 1.24), based on
41 cases among irradiated patients.
Since the relative risk of second cancers other than
leukaemia and contralateral breast cancer appeared to
be raised after a follow-up of five or more years, we
examined the relative risk by age-at-treatment. The
results are shown in Table 8. Raised relative risks were
observed in the 0 to 49 years and 50 to 64 years age-at-
treatment groups and, in the latter instance, this relative
risk was statistically significantly greater than one (RR =
2.36 (95% CI 1.08, 5.14) after adjustment for chemother-
apy and hormonal therapy). In contrast, there was no
evidence of a raised risk amongst those given radiother-
apy at age 65 years or more. We also examined the rela-
tive risk by age-at-risk, again based on a follow-up of
five or more years. As shown in Table 9, raised risks
were observed in all age-at-risk groups, although only
for the 65+ age-at-risk group was the relative risk close
to being statistically significant greater than 1 (RR =
2.04 (95% CI 0.96, 4.35) after adjustment for chemother-
apy and hormonal therapy), based on 15 cases among
irradiated patients.
For comparison purposes, an analysis was conducted
specifically for women who received chemotherapy or
hormonal therapy only. The relative risks for a follow-
up of five or more years are shown in Tables 10 and 11
respectively. The risk of all second cancers combined
was not raised, either overall or for different age-at-
Table 4 Relative risk of all second cancers among patients given radiotherapy, by age-at-treatment
Age-at-
treatment
(years)
RRa unadjusted for chemotherapy and
hormonal therapy (95% CIb)
RRa adjusted for chemotherapy and
hormonal therapy (95% CIb)
Cases/women with
radiotherapy
Cases/women with
no radiotherapy
<50 0.96 (0.60, 1.56) 0.87 (0.54, 1.43) 32/584 (5.5%) 45/632 (7.1%)
50 to 64 1.43 (0.88, 2.31) 1.35 (0.83, 2.20) 35/549 (6.4%) 37/687 (5.4%)
65+ 1.83 (0.65, 5.14) 1.69 (0.60, 4.76) 6/134 (4.5%) 12/494 (2.4%)
All 1.22 (0.88, 1.69) 1.14 (0.82, 1.58) 73/1,267 (5.8%) 94/1,813 (5.2%)
aRelative risk is calculated based on a follow-up of five or more years.
bConfidence interval.
Table 5 Relative risk of all second cancers among patients given radiotherapy, by age-at-risk
Age-at-risk
(years)
RRa unadjusted for chemotherapy and
hormonal therapy (95% CIb)
RRa adjusted for chemotherapy and
hormonal therapy (95% CIb)
Cases/women with
radiotherapy
Cases/women with
no radiotherapy
<50 0.84 (0.37, 2.02) 0.70 (0.29, 1.65) 11/569 (1.9%) 12/607 (2.0%)
50 to 64 1.14 (0.69, 1.87) 1.02 (0.62, 1.68) 28/926 (3.0%) 41/1,154 (3.6%)
65+ 1.69 (1.05, 2.73)* 1.65 (1.02, 2.68)* 34/482 (7.1%) 41/1,022 (4.0%)
*P < 0.05.
aRelative risk is calculated based on a follow-up of five or more years.
bConfidence interval.
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Table 6 Relative risk of all second cancers among patients given radiotherapy, by menopausal status
Postmenopausala RRb unadjusted for chemotherapy
and hormonal therapy (95% CIc)
RRb adjusted for chemotherapy and
hormonal therapy (95% CIc)
Cases/women
with radiotherapy
Cases/women with
no radiotherapy
Yes - natural 1.61 (1.13, 2.29)* 1.48 (1.04, 2.12)* 36/582 (6.2%) 49/1,072 (4.6%)
Yes - ovariectomy 1.40 (0.78, 2.45) 1.29 (0.73, 2.26) 4/63 (6.3%) 2/63 (3.2%)
No 0.90 (0.62, 1.32) 0.84 (0.58, 1.24) 33/621 (5.3%) 43/678 (6.3%)
*P <0.05.
aMenopausal status at the time of treatment.
bRelative risk is calculated based on a follow-up of five or more years.
cConfidence interval.
Table 7 Relative risk of site-specific second cancers among patients given radiotherapy
Cancer type Follow-
up
RRa unadjusted for chemotherapy
and hormonal therapy (95% CIb)
RRa adjusted for chemotherapy
and hormonal therapy (95% CIb)
Cases/women
with
radiotherapy
Cases/women with
no radiotherapy
Leukaemia > = 2
years
8.13 (0.96, 69.10)** 6.67 (0.76, 58.00) 7/2,339 (0.3%) 1/2377 (0.04%)
Contralateral
breast cancer
> = 5
years
0.87 (0.58, 1.32) 0.82 (0.54, 1.24) 41/1,267 (3.2%) 67/1,813 (3.7%)
All other
cancers
combined
> = 5
years
1.84 (1.06, 3.16)* 1.70 (0.98, 2.94)** 29/1,267 (2.3%) 29/1,813 (1.6%)
*P <0.05; ** P = 0.055.
aRelative risk.
bConfidence interval.
Table 8 Relative risk of other second cancers* among patients given radiation therapy, by age-at- treatment
Age-at-
treatment
RRa unadjusted for chemotherapy and
hormonal therapy (95% CIb)
RRa adjusted for chemotherapy and
hormonal therapy (95% CIb)
Cases/women with
radiotherapy
Cases/women with
no radiotherapy
<50 1.54 (0.60, 3.93) 1.36 (0.53, 3.51) 9/584 (1.5%) 10/632 (1.6%)
50 to 64 2.44 (1.12, 5.30)** 2.36 (1.08, 5.14)** 18/549 (3.3%) 11/687 (1.6%)
65+ 0.92 (0.18, 4.66) 0.82 (0.16, 4.13) 2/134 (1.5%) 8/494 (1.6%)
* Other second cancers are all second cancers other than contralateral breast cancer and leukaemia.
** P <0.05.
a Relative risk is calculated based on a follow-up of five or more years.
b Confidence interval.
Table 9 Relative risk of other second cancers* among patients given radiation therapy, by age-at- risk
Age-
at-risk
RRa unadjusted for chemotherapy and
hormonal therapy (95% CIb)
RRa adjusted for chemotherapy and
hormonal therapy (95% CIb)
Cases/women with
radiotherapy
Cases/women with no
radiotherapy
<50 2.12 (0.30, 15.07) 1.64 (0.22, 12.10) 3/569 (0.5%) 2/607 (0.3%)
50 to
64
1.67 (0.71, 3.91) 1.46 (0.62, 3.43) 11/926 (1.2%) 11/1,154 (1.0%)
65+ 2.07 (0.98, 4.35)** 2.04 (0.96, 4.35) 15/482 (3.1%) 16/1,022 (1.6%)
*Other second cancers are all second cancers other than contralateral breast cancer and leukaemia.
**P = 0.055.
a Relative risk is calculated based on a follow-up of five or more years.
bConfidence interval.
Table 10 Relative risk of all second cancers among patients given chemotherapy only, by age-at-treatment
Age-at-treatment (years) Relative Riska (95% CIb) P-value Cases/women with chemotherapy Cases/women with no chemotherapy
<50 0.37 (0.15, 0.91) 0.03 6/196 (3.1%) 34/367 (9.3%)
50 to 64 0.59 (0.17, 2.07) 0.4 3/67 (4.5%) 26/426 (6.1%)
65+ 0.00 >0.5 0/11 (0.0%) 10/333 (3.0%)
All 0.42 (0.20, 0.88) 0.02 9/274 (3.3%) 70/1,126 (6.2%)
aRelative risk is calculated based on a follow-up of five or more years.
bConfidence interval.
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treatment groups and in the case of chemotherapy the
risk was statistically significantly less than one. However,
the numbers of cases were very small.
The relative risk of all second cancers combined
among patients given radiotherapy plus chemotherapy
or/and hormonal therapy compared with patients given
radiotherapy only is shown in Table 12. In this cohort,
it appears to be that the patients who received radio-
therapy along with chemotherapy and/or hormonal ther-
apy had a lower risk of developing second cancers
compared with those patients received radiotherapy
alone.
Discussion
In this study, we have used a clinical records-based
cohort to analyse the effects of radiotherapy for breast
cancer on the incidence of subsequent second cancers.
All patients in this cohort received surgery for breast
cancer. The advantage of this approach is to minimise
any possible systematic difference between the irradiated
and non-irradiated groups by reducing variability in the
analysis. Such an approach has been used in other epi-
demiological studies of similar nature, as reported [17].
In our analysis, the relative risk for all second cancers
appeared to be increased five or more years after radio-
therapy compared to those non-irradiated. This is in
agreement with the epidemiological evidence for a
latency period of several years between exposure to
radiation and a raised risk of second cancers [20,24-26].
The increased relative risk for all second cancers was
observed in the 50 to 64 and 65+ years age-at-treatment
groups (Table 4). Since these groups largely consist of
post-menopausal patients, this finding may indicate an
association with menopausal status. Raised relative risks
were indeed observed among patients who were post-
menopausal or underwent ovariectomy and, in the case
of post-menopausal patients, were statistically signifi-
cant. For all second cancers other than contralateral
breast cancer and leukaemia, the risk variation by age-
at-treatment was slightly different (Table 8). Here the
increased risk was seen principally in the 50 to 64 year
age-at-treatment group. Nevertheless, the raised risk was
still linked with patients who had post-menopausal sta-
tus or underwent ovariectomy after adjustment for che-
motherapy and hormonal therapy, for example, RR =
2.16 (95% CI 1.22, 3.84) for post-menopausal patients;
RR = 1.87 (95% CI 0.75, 4.66) for patients who under-
went ovariectomy and RR = 1.05 (95% CI 0.52, 2.12) for
pre-menopausal patients. These findings are generally in
agreement with other studies that reported older age
was associated with an increased risk of a non-breast
second malignancy [19] and that most of the secondary
lung cancers occurred more than five years after radio-
therapy and in women who were >50 years at the time
of their breast cancer diagnosis [18].
Increased risk of leukaemia can arise two to five years
after exposure to radiation [27]. In our analysis, there
was suggestion of a raised incidence of leukaemia
among radiotherapy patients in the period two or more
years after radiotherapy. There were seven cases in the
radiotherapy group compared with only one case in
non-radiotherapy group, with a relative risk of 6.67 (95%
CI 0.76, 58.00) after adjustment for chemotherapy and
hormonal therapy. The raised risk was not statistically
significant, reflecting the small number of cases in this
cohort. An increased risk of leukaemia has also been
reported in previous epidemiological studies of breast
cancer patients treated with radiation [28]. This raised
Table 11 Relative risk of all second cancers among patients given hormonal therapy, by age-at-treatment
Age-at-treatment
(years)
Relative Riska (95%
CIb)
P-
value
Cases/women with hormonal
therapy
Cases/women with no hormonal
therapy
<50 0.57 (0.17, 1.92) 0.37 3/52 (5.8%) 34/367 (9.3%)
50 to 64 0.85 (0.38, 1.94) >0.5 8/187 (4.3%) 26/426 (6.1%)
65+ 0.52 (0.11, 2.42) 0.40 2/150 (1.3%) 10/333 (3.0%)
ALL 0.70(0.38, 1.30) 0.26 13/150 (8.7%) 70/333 (21.0%)
aRelative risk is calculated based on a follow-up of five or more years.
bConfidence interval.
Table 12 Relative risk of all second cancer due to combined therapy* compared with radiotherapy only
Age-at-treatment (years) Relative risk (95% CIa) P-value Cases/women with RT plus
chemotherapy or/and hormonal therapy
Cases/women with only RT
<50 0.43 (0.16, 1.14) 0.09 5/164 (3.0%) 27/420 (6.4%)
50 to 64 0.44 (0.15, 1.29) 0.14 4/142 (2.8%) 31/407 (7.6%)
65+ 0.82 (0.09, 7.51) >0.5 1/128 (0.8%) 5/106 (4.7%)
All 0.47 (0.23, 0.92) 0.03 10/334 (3.0%) 63/933 (6.7%)
*Radiotherapy plus chemotherapy or/and hormonal therapy.
aConfidence interval.
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risk might be associated with regional radiation therapy
that includes an internal mammary node field, which
may expose the thoracic spine to a relatively high radia-
tion dose [13]. Due to the small number of leukaemia
cases in this cohort, and there is no information avail-
able on leukaemia subtypes, analyses cannot be per-
formed regarding leukaemia subtypes after radiotherapy
in this study.
Raised risks of breast cancer have been reported in
various studies of women exposed to radiation; for
example, Japanese atomic bomb survivors [9,10,29],
female tuberculosis patients who received multiple fluor-
oscopies [30,31], and female patients who received
radiotherapy for various benign conditions [32]. The
risk was also seen in women who had direct breast
exposure prior to the age of 30 years [31-35]. However,
the causes of contralateral breast cancer amongst breast
cancer patients given radiotherapy are less obvious. In
the Early Breast Cancer Trialists’ Collaborative Group
report which evaluated the effects of radiotherapy, a sig-
nificantly increased risk of contralateral breast cancer
was found [5]. However, in another large case-control
study from Denmark, there was no significant raised
risk of contralateral breast cancer among women who
received radiotherapy [36]. A more recent large-scale
study included 13,472 women also failed to show an
increased risk of contralateral breast cancer for those
received radiotherapy [37]. In some studies, it was
reported that the increased risks of contralateral breast
cancer were most likely observed within the first year
following diagnosis of the primary breast cancer [38], or
associated with patients with more advanced stage dis-
ease [39-41]. Since some patients selected for post-mas-
tectomy radiation have a poorer prognosis than other
patients, there may well be bias in estimates of the risk
of contralateral breast cancer that can be attributed to
radiotherapy.
In our analysis, no raised relative risk for contralateral
breast cancer was observed during the period five or
more years after exposure. This is in agreement with
previous epidemiological studies [13,36,37,42]. Since our
analyses excluded the first five years following treat-
ment, we believe that this has excluded any effect of
metastatic disease in the opposite breast. However, our
result is based on a small number of cases, which makes
it difficult to detect any raised risk.
Other solid cancers have also been reported to link
with radiotherapy following breast cancer [14,43,44]. In
our analyses, the relative risk for all second cancer
excluding leukaemia and contralateral breast cancer
appeared to be increased five or more years after radio-
therapy. A statistically significantly increased risk was
observed in the 50 to 64 year age-at-treatment group.
This may indicate an association with menopausal
status.
With a fairly small total number of second cancers in
this cohort, the excess risk associated with radiotherapy
was small over the period of follow-up. Since many of
the women were still alive at the end of follow-up, the
possibility of raised risks continuing several decades
over radiotherapy cannot be ruled out and - based on
other studies [10] - would be expected.
The study of second cancers involves special problems
not inherent to most epidemiological investigations. For
a second primary cancer to be classified correctly, a
metastatic lesion or local recurrence of the original pri-
mary cancer must be ruled out. Other treatments may
affect subsequent cancer risks for certain organs, for
example, the ovary or uterus might be surgically
removed. Direct comparison between the irradiated and
non-irradiated groups is not without problems. The
non-exposed women generally have an earlier stage dis-
ease than do women treated with radiation, and the
expected number of second cancers among long term
survivors is often too small, as in our analysis, to permit
meaningful direct comparisons on a site-by-site basis.
It can also be argued that some of the second cancers
might occur due to factors other than radiotherapy,
such as a family history of breast cancer. It was esti-
mated that up to seven percent of breast cancer cases
are estimated to be due to breast cancer susceptibility
genes (for example, BRCA1, BRCA2, p53 and PTEN)
[45]. Although we do not have information on family
history of breast cancer, a previous study [46] reported
that there were increased risks of second cancers of the
oesophagus, stomach, ovary, non-Hodgkin’s lymphoma
and leukaemia in women with a family history of breast
cancer compared to those without such a history. There
might also be a joint effect of radiotherapy and cigarette
smoking on second cancer such as lung cancer. It was
reported [43] that radiotherapy increased the risk of sec-
ond primary lung cancer especially among ever smokers.
Although we cannot adjust for cigarette smoking in our
analysis, the effects of radiotherapy on lung cancer are
evident in our cohort since all four lung cancer cases
were occurred in the radiotherapy group (Table 2). This
is consistent with previous studies on lung cancer risk
after radiotherapy treatment [47,48]. The region of treat-
ment may also affect the risk of the second cancer. No
correlation was found with the region treated with
radiation but there was a trend for a higher risk of sec-
ond malignancy when the internal mammary nodes
were treated [49]. Our study supports this finding since
26% of radiotherapy patients in this cohort had the
mammary chain and supraclavicular nodes or chest wall
irradiated.
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It appears to be that the patients used radiotherapy
along with chemotherapy or/and hormonal therapy had
less risks of developing second cancers compared with
those patients received radiotherapy alone. However, we
do not have detailed information about the staging of
breast cancer at the time of diagnosis and what criteria
were based on for the prescription of different therapies.
Therefore, it is difficult to explain the reasons why the
use of chemo- and/or hormonal therapy combined with
radiotherapy might lead to a lower risk of second cancer
compared to the use of radiotherapy alone. However, it
is interesting to note that women who only received
chemotherapy or hormonal therapy did not have raised
risk of second cancer, although numbers of cases may
be too small to detect any raised risk in these subset
analyses.
Conclusions
This study indicated a raised risk of second malignan-
cies associated with radiotherapy for breast cancer. The
relative risk for second cancers appeared to be highest
for the 50 to 65 years age-at-treatment group during the
period five or more years after radiotherapy and this
might be related to the patients’ menopausal status.
Among specific types of cancer, there were raised risks
for leukaemia and for all cancers combined except leu-
kaemia and contralateral breast cancer. The risk of con-
tralateral breast cancer was not raised during the period
five or more years after radiotherapy.
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